The newfound coronavirus disease 2019 (COVID-19), initiated by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), is an international public health concern …

The world is in the midst of the coronavirus disease 2019 (COVID-19) pandemic. Interleukin
6 (IL-6) inhibitor (tocilizumab) had been suggested for the treatment of acute respiratory …

The description of a so-called cytokine storm in patients with COVID-19 has prompted
consideration of anti-cytokine therapies, particularly interleukin-6 antagonists. However …

Sepsis is a syndrome with high mortality, which seriously threatens human health. During
the pandemic of coronavirus disease 2019 (COVID-19), some severe and critically ill COVID …

The coronavirus disease 2019 pandemic caused by severe acute respiratory syndrome
coronavirus 2 presents with a spectrum of clinical manifestations from asymptomatic or mild …

Tocilizumab (TCZ), a monoclonal antibody against interleukin‐6 (IL‐6), emerged as an
alternative treatment for COVID‐19 patients with a risk of cytokine storms recently. In the …

Summary Objectives Multiple RCTs of interleukin-6 (IL-6) inhibitors in COVID-19 have been
published, with conflicting conclusions. We performed a meta-analysis to assess the impact …

Since December 2019, a novel coronavirus pneumonia (COVID-19) has broken out in
Wuhan, China and spread rapidly. Recent studies have found that⁓ 15.7% of patients …

Elevated concentrations of interleukin-6 have been demonstrated to be an important key
factor in COVID-19 host immune impairment. It represents an important prognostic factor of …

Objectives Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated
with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our …